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Abstract
Background: Antimicrobial resistance of Neisseria gonorrhoeae is a serious health problem in China. Gonococcal
antimicrobial susceptibility has been monitored in Shanghai since 1988. In this study, we examined the changing
pattern of gonococcal antimicrobial susceptibility based on data from N. gonorrhoeae isolates collected over the
past 25 years.
Methods: Approximately 100–200 isolates each year (1988–2013) were tested for their susceptibility to penicillin
(PEN), tetracycline (TET), ciprofloxacin (CIP), ceftriaxone (CRO) and spectinomycin (SPT), using the agar dilution
method. Plasmid-mediated N. gonorrhoeae antimicrobial resistance, comprising penicillinase-producing N. gonorrhoeae
(presumed PPNG) and high-level tetracycline resistance N. gonorrhoeae (presumed TRNG), were also determined.
Breakpoints for susceptibilities followed those described by the Clinical and Laboratory Standard Institute and the
European Committee on Antimicrobial Susceptibility Testing.
Results: A high proportion of isolates were resistant to PEN, TET and CIP, ranging from less than 20% at the beginning
of the survey, increasing in the late 1990s and reaching over 90% in recent years. The proportion of isolates exhibiting
plasmid-mediated resistance exceeded 38% for presumed PPNG and 20% for presumed TRNG in recent years. The
proportion of CRO nonsusceptible isolates (MIC≥ 0.125 mg/L) ranged from 7% to 13% in most of the study years.
Almost all isolates were susceptible to SPT. The SPT MIC90 was 16–32 mg/L for 2008–2013. The proportion of CRO
nonsusceptible-associated multiple-drug-resistant (MDR) isolates was over 5% in most of the study years.
Conclusions: N. gonorrhoeae isolates in Shanghai were resistant to PEN, TET and CIP. Furthermore, CRO nonsusceptible
and MDR isolates were prevalent. N. gonorrhoeae isolates were also found to be susceptible to SPT. It is recommended
that the CRO dose be increased from currently recommended 250 mg to 500 mg and that SPT be an alternative in
treating urogenital gonorrhea. Our findings highlight the importance of both regional and national surveillance
programs for the prompt modification of treatment guidelines, vital in responding to the changing pattern of
gonococcal antimicrobial susceptibility.
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Background
Neisseria gonorrhoeae, a Gram-negative bacterium, is re-
sponsible for the sexually transmitted disease gonorrhea.
In 2008, over 106 million new cases of N. gonorrhoeae
were reported worldwide [1]. In China, infectious disease
surveillance reports more than 100,000 new gonorrhea
cases each year. In 2012, there were 95,263 gonorrhea
cases reported in China with an incidence rate of 7.07 per
100,000 population. Gonorrhea ranked sixth in the most
frequently reported infectious diseases in China [2]. There
are currently no vaccines available for N. gonorrhoeae [3].
Antimicrobial treatment is essential to control this infec-
tious disease. However, antimicrobial resistance (AMR) in
N. gonorrhoeae is emerging as a significant public health
problem worldwide [4,5]. In most areas of the world, N.
gonorrhoeae has developed resistance to sulfonamides,
penicillins, tetracyclines, macrolides and fluoroquinolones
[6]. Decreased susceptibility, sporadic resistant isolates
and clinical treatment failure to oral or parental third-
generation cephalosporins have also been observed [7-10].
Moreover, extensive/multiple-drug-resistant (MDR) N.
gonorrhoeae isolates are commonly observed in various
areas of the world [8,10].
In China, the burden of gonococcal penicillin (PEN) and
tetracycline (TET) resistance reached high levels [11-13].
In response, fluoroquinolones were introduced as a treat-
ment option. Since 1995, orally administered ciprofloxacin
(CIP) has been recommended for the treatment of gonor-
rhea in China. However, as a result, the proportion of CIP
resistance drastically increased from 15% in 1996 to nearly
100% in the mid-2000s in China [11-13]. The use of CIP
for the treatment of gonorrhea has since been terminated
in China [14,15]. Since 2007, ceftriaxone (CRO) has been
recommended as the first line drug for the treatment of
gonorrhea in China [14]. However, in Shanghai CRO has
been used since 2000, and the presence and spread of
gonococcal isolates with nonsusceptibility to CRO (min-
imal inhibitory concentration (MIC) = 0.125–0.25 mg/L)
was reported in 11.9% of isolates in 2005 and 19.7% of
isolates in this city in 2008 [11,12].
In this study, we used the data of the Shanghai Gonococ-
cal Antimicrobial Susceptibility Surveillance Program from
N. gonorrhoeae isolates collected over the past 25 years to
analyze trends in AMR development in Shanghai. The
AMR data were aligned with the timeline of treatment
guidelines for gonorrhea in China. We found that N. gonor-
rhoeae isolates in Shanghai were resistant to PEN, TET and
CIP, which were historically used for the treatment of gon-
orrhea in this region. Plasmid-mediated N. gonorrhoeae
antimicrobial resistance has been prevalent in the past
decades. High proportions of N. gonorrhoeae isolates are
nonsusceptible to the currently recommended treatment
regime of CRO (MIC ≥ 0.125). In Shanghai, MDR associ-
ated with the CRO nonsusceptible phenotype was prevalent
in N. gonorrhoeae isolates. Our report indicates the useful-
ness of regional surveillance data in the modification of
treatment guidelines and provides insights that will be
important in future strategic planning for the treatment of
gonorrhea.
Methods
Collection of N. gonorrhoeae isolates
The Shanghai Gonococcal Antimicrobial Susceptibility
Surveillance Program was established in 1988 and has
been led by the Shanghai Skin Disease Hospital (SSDH),
Shanghai, China. The number of gonorrhea cases
reported by the SSDH was approximately 14–16% of the
reported cases from the entire Shanghai city over the
years [16]. The number of gonococcal isolates tested for
antimicrobial susceptibility accounted for about 10% of
the SSDH reported cases or 2.1% of reported cases in
Shanghai in 2012. All of the surveyed N. gonorrhoeae
isolates were from the Sexually Transmitted Infection
Clinic of the SSDH.
Each year in the SSDH, approximately 100–200N. gonor-
rhoeae isolates were collected from individual patients for
antimicrobial susceptibility testing. The first 10–20N.
gonorrhoeae isolates each month were collected from
patients with culture positive gonorrhea [12]. During the
period from 1988 to 2000, N. gonorrhoeae isolates were
collected from both male and female patients, and during
the period from 2001 to 2013, N. gonorrhoeae isolates were
only collected from male patients. N. gonorrhoeae was
isolated and cultured as previously described [12].
Gonococcal isolates were collected as part of standard
patient care, and ethics approval was not required for
their use.
Determination of the minimal inhibitory
concentrations (MIC)
The antimicrobial susceptibility of N. gonorrhoeae isolates
was determined using the agar dilution method [17] at the
Laboratory Diagnostic Centre of the SSDH. WHO refer-
ence strains A, B, C, D and E were used in susceptibility
tests [12]. Five antimicrobial agents were tested against N.
gonorrhoeae isolates: PEN (0.002–32.0 mg/L), TET (0.002–
32.0 mg/L), CIP (0.002–32.0 mg/L), spectinomycin (SPT;
2.0–128.0 mg/L) and CRO (0.002–2.0 mg/L). Antimicro-
bial agents were provided by the China GASP at the
National Center for Sexually Transmitted Disease Control,
China (1988–2002) or purchased from Sigma-Aldrich
(Distributor: the Shanghai ANPEL Scientific Instrument
Co. Ltd., Shanghai, China). The MIC testing was per-
formed on GC agar base supplemented with 1% IsoVitalex
as previously described [12]. Each MIC determination was
performed in duplicate. Gonococcal isolates with inconsist-
ent CRO MICs between the duplicates were re-tested.
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Determination of plasmid-mediated resistance in N.
gonorrhoeae isolates
Beta-lactamase producing N. gonorrhoeae (PPNG) isolates
were determined using the chromogenic cephalosporin test
before 2003 and the nitrocefin test in 2003–2013 (Oxoid;
distributed by GuangZhou LOSO Science Ltd.) [12]. All
N. gonorrhoeae isolates were tested for β-lactamase
production. Plasmid-mediated tetracycline-resistant N.
gonorrhoeae (TRNG) isolates were defined as those
having a TET MIC of ≥ 16.0 mg/L. PP/TRNG isolates
were defined as those isolates that were β-lactamase
positive and had a TET MIC of ≥ 16 mg/L. Therefore,
the characterizations for presumed PPNG and TRNG
were solely based on the detection of β-lactamase and
the TET MIC, respectively.
Criteria for resistant phenotypes of N. gonorrhoeae
Breakpoints for the susceptibilities to PEN, TET, CIP
and SPT were those described by the Clinical Laboratory
Standards Institute (CLSI) [17]. The classifications of
resistance phenotypes included PEN resistance (MIC ≥
2.0 mg/L), TET resistance (MIC ≥ 2.0 mg/L), CIP resist-
ance (MIC ≥ 1.0 mg/L) and SPT resistance (MIC ≥
128.0 mg/L). Chromosomally-mediated resistant N.
gonorrhoeae (CMRNG) isolates exhibited a PEN MIC
of ≥ 2.0 mg/L, a TET MIC of ≥ 2.0 mg/L and were not
classified as PPNG or TRNG. For CRO susceptibility,
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) breakpoint was followed (nonsuscep-
tible, MIC ≥ 0.125 mg/L) [18]. In this study, the suscepti-
bilities to CRO in N. gonorrhoeae were further
categorized as susceptible (MIC ≤ 0.03 mg/L), reduced
susceptibility (MIC = 0.06) and nonsusceptible (MIC ≥
0.125 mg/L) [11]. The MDR phenotypes of N. gonor-
rhoeae were defined as various combinations of the
above resistant phenotypes (Table 1).
Results
N. gonorrhoeae has become less susceptible to CRO
During the period from 1995 to 2013, 3153N. gonorrhoeae
isolates were examined for their susceptibility to CRO
(Table 2). Overall, 71.90% isolates were susceptible to CRO
(MIC ≤ 0.03 mg/L); 20.30% had a reduced susceptibility
phenotype (MIC = 0.06 mg/L) and 7.80% exhibited a CRO
nonsusceptible phenotype (MIC ≥ 0.125 mg/L). The high-
est CRO MIC value for the N. gonorrhoeae isolates was
0.25 mg/L, which accounted for 0.92% of the isolates tested
(29/3153).
The proportions of CRO non-susceptible isolates were
over or equal to 5% in all years since 1998, and were
around 7%-13% in the last 3 years (2011 to 2013). The
proportion of isolates showing reduced susceptibility to
CRO ranged from 12% to 40% from 1998 to 2013. From
1998 to 2013, the MIC50 values for CRO were between
0.015 mg/L and 0.06 mg/L, and the MIC90 values were
0.06–0.125 mg/L (Table 2).
N. gonorrhoeae is resistant to CIP, PEN and TET
During the period from 1996 to 2013, 3036N. gonorrhoeae
isolates were examined for susceptibility to CIP. Overall,
85.30% isolates were resistant to CIP. CIP resistant N.
gonorrhoeae accounted for 16.50% of the N. gonorrhoeae
isolates in 1996, compared with over 85% in 1999. CIP
resistance among the isolates ranged from 88% to 100% in
the period between 2000 and 2013 (Additional file 1:
Figure S1). A total of 3663N. gonorrhoeae isolates were
examined for their susceptibility to PEN. Overall, 62.00%
isolates were resistant to PEN. Proportions of PEN resist-
ance increased from 20–40% before 1998, to 70–90%
during the period from 2000 to 2013 (Additional file 1:
Figure S1). During the period from 1995 to 2013, 3153N.
gonorrhoeae isolates were examined for their susceptibility
to TET. Only one concentration of TET (16 mg/L) was
tested during 1998–2003 (n = 1355), whereas the
remaining 1798N. gonorrhoeae isolates were tested for the
full range of TET concentrations. For the 1798 isolates
tested during 1995–1997 and 2004–2013, 50.61% (910/
1798) were resistant to TET. The proportion of TET resist-
ant isolates increased from 16% (1995–1997) to over 40%
(2004–2012), and then further increased to 82.57% in 2013
(Additional file 1: Figure S1).
Susceptibility of N. gonorrhoeae isolates to SPT
From 1995 to 2013, 3153N. gonorrhoeae isolates were ex-
amined for their susceptibility to SPT. Only two resistant
Table 1 Criteria for the phenotypes of multiple drug
resistance in N. gonorrhoeae
Resistant phenotype PEN TET CIP CRO
CMRNG ≥2 ≥2 na na
PEN-TET ≥2 ≥2 na na
PEN-CIP ≥2 na ≥1 na
PEN-CRO ≥2 na na ≥0.125
TET-CIP na ≥2 ≥1 na
TET-CRO na ≥2 na ≥0.125
CIP-CRO na na ≥1 ≥0.125
PEN-TET-CIP ≥2 ≥2 ≥1 na
PEN-TET-CRO ≥2 ≥2 na ≥0.125
PEN-CIP-CRO ≥2 na ≥1 ≥0.125
TET-CIP-CRO na ≥2 ≥1 ≥0.125
PEN-TET-CIP-CRO ≥2 ≥2 ≥1 ≥0.125
CMRNG: chromosomally-mediated resistant N. gonorrhoeae, non-penicillinase-
producing N. gonorrhoeae (Non-PPNG) and tetracycline MIC <16 mg/L.
PEN: penicillin; TET: tetracycline; CIP: ciprofloxacin; CRO: ceftriaxone
(nonsusceptible); na: not applicable; MICs are presented as mg/L;
Spectinomycin (SPT) was not listed.
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isolates (0.06%, MIC ≥ 128 mg/L) were identified, one in
1999 and the other in 2002. Overall, isolates with inter-
mediate resistance (MIC = 64 mg/L) accounted for 6.76%,
and the related proportion of susceptible isolates was
93.18%. During the period from 2009 to 2013, the propor-
tion of isolates with an SPT MIC ≥ 64 mg/L was less than
5% (4.46% in 2009, 0% in 2010, 2.22% in 2011 and 0% in
2012 and 2013), with the SPT MIC50 ranging between
4 mg/L and 32 mg/L during this period. The majority of
SPT MIC90 values were 16–32 mg/L, and the values of
MIC90 in 2003 and 2007 were 64 mg/L (data not shown).
Plasmid-mediated and chromosomally-mediated resistant
N. gonorrhoeae
In 1995, only 0.85% of isolates exhibited a presumed
PPNG phenotype. Around 5% of isolates were presumed
PPNG from 1996 to 1998. The proportion of presumed
PPNG isolates increased rapidly from 13% in 1999 to
37% in 2000 and ranged from 37% to 57% during the
period from 2001 to 2013 (Additional file 1: Figure S2).
The proportion of presumed TRNG isolates was 0–1%
for the period from 1995 to 1998, and increased to
7.69% and 6.67% for 1999 and 2000, respectively. During
2001–2005, the proportion of presumed TRNG was
around 17% - 23%. This proportion again increased from
30% (2006) to 56% (2008), and remained above 30%,
from 2009 to 2013 (Additional file 1: Figure S2). There
were no PP/TRNG isolates detected during the first
4 years of surveillance (1995–1998). The proportion of
presumed PP/TRNG isolates was 0.48% and 1.78% for
1999 and 2000, respectively. This proportion increased
rapidly to 12–14% during the period from 2001 to 2005
and remained above 15% between 2006 and 2013, peak-
ing at 33.8% in 2008 (Additional file 1: Figure S2).
The proportion of chromosomally-mediated resistance
to PEN and TET among the 1569 CMRNG isolates from
2003 to 2013 ranged from 4.23% to 29.14%. In recent
years, the proportion of CMRNG isolates detected has
been 15.56% (2011), 6.06% (2012) and 23.85% (2013).
Multiple drug resistance (MDR) in N. gonorrhoeae
An MDR phenotype for N. gonorrhoeae was defined as
resistance to two or more antimicrobial agents (Table 1).
Double-resistant phenotypes accounted for 39–68%
(PEN-TET), 61–92% (PEN-CIP) and 43–81% (TET-CIP)
of N. gonorrhoeae isolates, and the triple-resistant
phenotype (PEN-TET-CIP) accounted for 38–61% of N.
gonorrhoeae isolates during the period from 2003 to
2013 (data not shown).
Table 2 Susceptibility of N. gonorrhoeae isolates to ceftriaxone in Shanghai
Year N Reduced* Nonsusceptible** MIC50 MIC90 MIC range
n % n % (mg/L) (mg/L) (mg/L)
1995 117 0 0.00 0 0.00 0.008 0.015 0.008-0.03
1996 206 2 0.97 2 0.97 0.008 0.03 0.002-0.25
1997 208 7 3.37 2 0.96 0.008 0.03 0.002-0.25
1998 180 29 16.11 14 7.78 0.03 0.06 0.004-0.25
1999 208 27 12.98 12 5.77 0.015 0.06 0.002-0.25
2000 225 47 20.89 15 6.67 0.03 0.06 0.004-0.25
2001 230 39 16.96 16 6.96 0.03 0.06 0.004-0.25
2002 210 30 14.29 20 9.52 0.03 0.06 0.004-0.25
2003 302 57 18.87 34 11.26 0.03 0.125 0.004-0.25
2004 166 53 31.93 20 12.05 0.03 0.125 0.004-0.25
2005 83 26 31.33 5 6.02 0.03 0.06 0.004-0.125
2006 128 51 39.84 18 14.06 0.06 0.125 0.008-0.25
2007 200 64 32.00 10 5.00 0.03 0.06 0.004-0.25
2008 71 25 35.21 14 19.72 0.06 0.125 0.008-0.125
2009 157 36 22.93 18 11.46 0.03 0.125 0.008-0.125
2010 119 34 28.57 9 7.56 0.03 0.06 0.008-0.125
2011 135 55 40.74 14 10.37 0.06 0.125 0.008-0.125
2012 99 14 14.14 7 7.07 0.03 0.06 0.004-0.125
2013 109 43 39.45 15 13.76 0.06 0.125 0.004-0.25
Total 3153 639 20.30 245 7.80
*: CRO MIC = 0.06 mg/L; **: CRO MIC ≥ 0.125 mg/L.
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Between 2001 and 2013, the proportion of the CRO non-
susceptible phenotype combined with PEN, TET or CIP re-
sistance fluctuated from 4.5% to 19.72% (PEN-CRO),
2.41% to 12.68% (TET-CRO) or 0% to 19.72% (CIP-CRO)
(Table 3). CRO-associated triple-resistant phenotypes
accounted for 2.41–12.68% (PEN-TET-CRO), 2.41–12.68%
(TET-CIP-CRO) and 2.17–19.72% (PEN-CIP-CRO) of
N. gonorrhoeae isolates (Table 3), and the proportion of
quadruple resistant phenotypes (PEN-TET-CIP-CRO)
accounted for 2.41–12.68% of N. gonorrhoeae isolates
(Table 3).
Discussion
In China, antibiotic resistance of N. gonorrhoeae has
become an increasing problem over the past few decades
in the treatment of gonorrhea infection. Since the mid-
1990s, a high proportion of N. gonorrhoeae isolates sam-
pled in Shanghai were resistant to PEN, TET and CIP.
Plasmid-mediated resistance has been highly prevalent
since the early 2000s. The proportion of N. gonorrhoeae
isolates exhibiting a CRO nonsusceptible phenotype
(MIC ≥ 0.125 mg/L) has been greater than 5% since
1998. In 2013, 13.76% of isolates exhibited a CRO MIC
of ≥ 0.125 mg/L, suggesting that the effectiveness of the
currently recommended treatment regime for gonorrhea
is diminishing. MDR phenotypes associated with PEN,
TET and CIP resistance were prevalent. N. gonorrhoeae
isolates exhibiting a CRO nonsusceptible phenotype as-
sociated MDR were also found to be prevalent in recent
years. In Shanghai, N. gonorrhoeae isolates were found
to be susceptible to SPT.
The CRO MIC of N. gonorrhoeae isolates has been ex-
tensively monitored. In the United States, the proportion
of isolates with elevated CRO MICs (≥0.125 mg/L)
ranged from 0.1% to 0.4% between 2006 and 2012 [19].
In Canada, 7.3% of N. gonorrhoeae isolates showed CRO
MICs ≥ 0.125 mg/L in 2010 [20]. In England and Wales
during 2007–2011, 0–0.4% of N. gonorrhoeae isolates
showed CRO MICs ≥ 0.125 mg/L [4]. In Australia, no
isolates of N. gonorrhoeae with CRO MIC values ≥
0.125 mg/L were reported in 2011 [21,22]. In Latin
America and the Caribbean countries, 0.4% of N. gonor-
rhoeae isolates had CRO MICs ≥ 0.125 mg/L between
2007 and 2011 [23].
In the present study, we found that the proportion of
N. gonorrhoeae isolates with CRO MICs ≥ 0.125 mg/L in
Shanghai (1996–2013) greatly varied from year to year,
ranging from 0% (1995) to 19.72% in 2008, and 13.76%
in 2013. Our findings were consistent with those of a
survey of CRO susceptibility in Nanjing, China [24,25].
The proportion of CRO less susceptible N. gonorrhoeae
isolates (CRO MIC ≥ 0.06 mg/L) was 17.86–50.5%
during the period from 1999 to 2006 in Nanjing [24].
Chen et al. reported that the proportion of isolates with
a CRO MIC = 0.125 mg/L was 39.4% in 2007 and 11.3%
in 2012 [25]. The proportion of CRO nonsusceptible iso-
lates (MIC ≥ 0.125 mg/L) ranged from 22% to over 48%
in Nanning in 2000–2012 [26], much higher than that
detected in Shanghai. Regional differences in gonococcal
AMR within a country have also been demonstrated in
other countries. In Canada, isolates of N. gonorrhoeae
from the province of Saskatchewan retained a high
prevalence of susceptibility to antibiotics, including CIP
and PEN and CRO. Unlike reports of reduced suscepti-
bility to third-generation cephalosporins (CRO or cefix-
ime) from other regions of Canada and the rest of the
world, all isolates collected during 2003–2008 from
Saskatchewan were fully susceptible to CRO and cefix-
ime [27]. Approximately 7% of the isolates (n = 23)
showed a CRO MIC of 0.03–0.06 mg/L, and 93% of the
Table 3 MDR associated with the CRO nonsusceptible phenotype in N. gonorrhoeae isolates in Shanghai
Year N PEN-CRO TET-CRO CIP-CRO PEN-TET-CRO TET-CIP-CRO PEN-CIP-CRO PEN-TET -CIP-CRO
2001 230 6.52% - 6.52% - - 2.17% -
2002 210 7.62% - 9.52% - - 3.81% -
2003 302 9.60% 9.93% 10.26% 8.94% 8.94% 8.61% 7.95%
2004 166 12.05% 7.83% 12.05% 7.83% 7.83% 12.05% 7.83%
2005 83 6.02% 2.41% 0.00% 2.41% 2.41% 6.02% 2.41%
2006 128 12.50% 7.03% 13.28% 6.25% 7.03% 12.50% 6.25%
2007 200 4.50% 3.00% 5.00% 2.50% 3.00% 4.50% 2.50%
2008 71 19.72% 12.68% 19.72% 12.68% 12.68% 19.72% 12.68%
2009 157 11.64% 7.64% 11.46% 7.64% 7.64% 11.46% 7.64%
2010 119 7.56% 7.56% 7.56% 7.56% 7.56% 7.56% 7.56%
2011 135 10.37% 8.15% 10.37% 8.15% 8.15% 10.37% 8.15%
2012 99 6.06% 5.05% 7.07% 5.05% 5.05% 6.06% 5.05%
2013 109 11.93% 10.09% 13.76% 9.17% 10.09% 11.93% 9.17%
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isolates (n = 297) showed a CRO MIC of < 0.03 mg/L
[27]. In Canada between 2000 and 2009 (n = 40,875), the
proportions of PEN, TET or CIP resistant isolates were
11.8%, 21.3% and 13.2%, respectively; and the CRO MIC
had shifted from 0.016 mg/L in 2000 to 0.063 mg/L in
2009 [28]. In British Columbia (2006–2011), 13% of
isolates (227/1837) showed a CRO MIC of 0.064 mg/L
and 1% of isolates (27/1837) showed a CRO MIC of
0.125 mg/L [29]. Indeed, cefixime treatment failure was
found in 3.09% of the investigated cases (9/291) in
Toronto between 2010 and 2011 [9]. Taking all of these
data into account, it is clear that regional monitoring of
N. gonorrhoeae AMR is as important as national surveil-
lance programs.
Currently, the recommended therapy for gonorrhea is a
single dose of oral or parental third-generation cephalo-
sporin. The doses of CRO used for the treatment of un-
complicated gonorrhea vary among countries; typically
250–500 mg per dose is injected intramuscularly, but in
Japan 1 g is administered intravascularly [14,23,30-34]. A
landmark study suggested that increasing the dose of
CRO is associated with a decreased proportion of CRO
nonsusceptible N. gonorrhoeae isolates in the UK [4].
However, this decrease may not be sustainable [21]. We
observed that the proportion of CRO nonsusceptible iso-
lates transiently increased from 5% in 2007 when CRO
became a recommended drug in China, to over 19% in
2008, 11% in 2009 and 13% in 2013. In Shanghai, CRO at
a single low dose (250 mg) has been used to treat uncom-
plicated gonorrhea since 2000, and the proportion of CRO
nonsusceptible N. gonorrhoeae isolates remains fairly
stable. Based on our findings and reports from others in
China [24-26], CRO remains an effective antimicrobial for
the treatment of uncomplicated gonorrhea. Since CRO
nonsusceptible N. gonorrhoeae isolates are prevalent in
China, a higher dose of CRO (500 mg) is recommended,
at least in some areas such as Shanghai, Nanjing and
Nanning [24-26].
Detailed data on trends of MDR of N. gonorrhoeae in
China are limited. However, with the consideration of
the high resistant proportions of gonococcal isolates to
PEN, TET, and CIP, non-susceptible CRO-associated
MDR should not be ignored in China. We observed that
over 5% of isolates were non-susceptible CRO-associated
MDR in Shanghai in recent years.
One of the major purposes of antimicrobial susceptibil-
ity surveillance is to provide information that may indicate
the need for modification of treatment guidelines. The
World Health Organization recommended that when the
prevalence of resistant gonococci to an antimicrobial
agent rises to 5%, the antimicrobial should no longer be
used [35]. In China, PEN had been the treatment of choice
for gonorrhea until quinolones were introduced in 1993,
PEN was removed from the treatment regime in 2000
[14,15]. Before 2000, the recommended dose of PEN
continually increased because of a progressive decline in
susceptibility. Penicillin was removed from the treatment
regime 10 years after it was discontinued in 1985 in most
regions of the world, simply because of the availability of
replacing antibiotics. In 1993, oral fluoroquinolones (CIP
and ofloxacin) were recommended for gonorrhea treat-
ment, and at that time CIP resistance was already 15% in
China [12,13]. Four years after (1997), CIP resistance
reached over 80% (100% in 2000), while the drug remained
in the treatment regime until 2007 [14].
Recently potential novel treatment strategies have
been explored [6,7]. A strategy of combining older drugs
was discussed [36-38]. However, there is no evidence
that this combination of older drugs produces synergistic
effects. Considering the problems of MDR, this strategy
should be used with caution in China. A high preva-
lence of MDR to almost all currently available drugs in
Shanghai limits options for combined therapy. New anti-
biotics are needed but are largely unavailable [38]. It is
therefore worth considering and evaluating SPT as an al-
ternative first line drug for the treatment of uncompli-
cated urogenital gonorrhea in China. However, SPT is not
suitable for the treatment of pharyngeal gonorrhea even
though the prevalence of resistance is low in most areas of
the world [39]. The MICs of SPT need to be closely moni-
tored, and any signs of increased SPT MIC warrant a thor-
ough investigation and close attention by the policy
makers.
The current study has a number of limitations. 1) All of
the N. gonorrhoeae isolates tested in this study were col-
lected from the Sexually Transmitted Infection Clinic of
the SSDH, and only a small number of isolates were tested,
accounting for 2.1% of the total reported cases in 2012 in
Shanghai. 2) A lack of demographic and clinical data pre-
vented any comparisons of N. gonorrhoeae antimicrobial
resistance profiles with patient characteristics; 3) Molecular
subtyping of the isolates was not performed. This would
provide insight into whether there is clonal spread of resist-
ant isolates and should be the focus of future studies. 4)
The agar dilution MIC testing method has an intrinsic
error rate of plus/minus one dilution. While using a break-
point of 0.125 mg/L for CRO nonsusceptible isolates, some
isolates may actually have MICs of 0.06 mg/L.
Conclusions
In summary, antimicrobial resistance of N. gonorrhoeae to
PEN, TET and CIP is highly prevalent in Shanghai. A high
proportion of N. gonorrhoeae isolates were found to be
CRO nonsusceptible (MIC ≥ 0.125 mg/L). Plasmid-
mediated resistance and MDR are also prevalent in China.
N. gonorrhoeae isolates are susceptible to SPT and this
antibiotic needs to be further evaluated as a treatment op-
tion for urogenital gonococcal infections. Our findings
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suggest that the CRO dose should be increased to 500 mg
in areas with a high prevalence of CRO nonsusceptible
isolates. We propose that combination therapy using older
antibiotics should be used with caution unless drug syner-
gistic effects can be confirmed. Finally, both national and
regional antimicrobial susceptibility surveillance programs
are important to inform policy makers in a timely manner
on the appropriate modifications of treatment guidelines.
Additional file
Additional file 1: Figure S1. Resistant proportions of N. gonorrhoeae
isolates to CIP, PEN and TET. Closed diamond solid line: CIP resistant;
Open square dashed line: PEN resistant; Closed triangle solid line: TET
resistant. Surveillance of PEN susceptibility started in 1988, and data to
PEN in 1990, 1991 and 1994 were not available. Surveillance of CIP and
TET susceptibility started in 1995 (TET) and 1996 (CIP). During 1998–2002,
TET was examined only at a concentration of 16 mg/L, and proportions
of resistance were unavailable. N: number of isolates tested. R: resistant.
Figure S2. Proportions of plasmid-mediated resistance in N. gonorrhoeae.
Closed diamond solid line: Penicillinase-producing N. gonorrhoeae
(presumed PPNG); Open square dashed line: High level TET resistance
N. gonorrhoeae (presumed TRNG); Closed triangle dashed line: presumed
PP/TRNG. N: number of isolates tested.
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